Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00288080 · ClinicalTrials.gov registry record · Phase 3
Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer
A Phase 3 study, sponsored by Radiation Therapy Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
- 612
- Enrollment target
NCT00288080 is a Phase 3 study that has completed, run by Radiation Therapy Oncology Group. The registered enrollment target is 612 participants.
The verdict
NCT00288080, a Phase 3 study, has completed, sponsored by Radiation Therapy Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 612 participants
- Enrollment target
Study Summary
RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer by lowering the amount of androgens the body makes. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving hormone therapy and radiation therapy together with chemotherapy is more effective than giving hormone therapy together with radiation therapy in treating prostate cancer. PURPOSE: This randomized phase III trial is studying hormone therapy and radiation therapy followed by docetaxel and prednisone to see how well it works compared to hormone therapy and radiation therapy in treating patients with localized prostate cancer.
Interventions
- DRUG Dexamethasone
- DRUG Prednisone
- RADIATION Radiation therapy
- DRUG docetaxel
- DRUG Oral antiandrogen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2005-12 |
| Est. Completion | 2022-05-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00288080
The ClinicalTrials.gov registry entry for NCT00288080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radiation Therapy Oncology Group, which has 144 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT00288080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00288080 about?
NCT00288080 is a clinical study titled "Hormone Therapy and Radiation Therapy or Hormone Therapy and Radiation Therapy Followed by Docetaxel and Prednisone in Treating Patients With Localized Prostate Cancer". RATIONALE: Androgens can cause the growth of prostate cancer cells. Hormone therapy using drugs, such as leuprolide, goserelin, flutamide, or bicalutamide, may fight prostate cancer by lowering the amount of androgens the body makes. Radiation therapy uses high-energy x-rays to kill tumor cells. Dru...
What is the current status of trial NCT00288080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 612 participants. The study started on 2005-12. Estimated completion is 2022-05-20.
What interventions are being tested in trial NCT00288080?
The interventions under investigation include: Dexamethasone (DRUG), Prednisone (DRUG), Radiation therapy (RADIATION), docetaxel (DRUG), Oral antiandrogen (DRUG).
Who is sponsoring clinical trial NCT00288080?
This trial is sponsored by Radiation Therapy Oncology Group, which has 144 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.